A multidisciplinary approach to the changing management of Stage III melanoma patients: New developments in surgical and systemic therapy | Overview 0/1
Management of Stage III melanoma has evolved in recent years and effective systemic therapies are now being used in high risk early stage melanoma patients to reduce the risk of recurrence and improve survival. This advancement in treatment has made sentinel node biopsy (SNB) essential for accurate clinical decision-making.
Surgical Oncologist, Prof Spillane, discusses the role of SNB and completion lymph node dissection, the current practice undertaken at Melanoma Institute Australia and the implications this has for adjuvant therapy. Medical Oncologist, A/Prof Menzies, then outlines recent data from adjuvant systemic therapy clinical trials, discusses how these data translate to the current clinical setting, and offers insights into future developments of adjuvant and neoadjuvant therapy in melanoma.
Prof Andrew Spillane - Surgical Oncologist, Melanoma Institute Australia | Professor of Surgical Oncology, The University of Sydney
A/Prof Alexander Menzies - Medical Oncologist, Melanoma Institute Australia, Royal North Shore and Mater Hospitals | Associate Professor of Melanoma Medical Oncology, The University of Sydney
This activity has been RACGP Accredited for 2 Category 2 points.
Outline the new developments in surgical and systemic therapy and the GP role in the multidisciplinary management of Stage III melanoma.